| Literature DB >> 25325023 |
Orhun Sinanoglu1, Sinan Ekici1, Mb Can Balci1, A Ismet Hazar1, Baris Nuhoglu1.
Abstract
PURPOSE: To compare urethral stricture rates in comorbid patients undergoing plasmakinetic transurethral resection of the prostate (PK-TURP) and monopolar transurethral resection of the prostate (M-TURP) for benign prostatic hyperplasia.Entities:
Keywords: Comorbidity; Prostatic hyperplasia; Transurethral resection of prostate; Urethral stricture
Year: 2014 PMID: 25325023 PMCID: PMC4186955 DOI: 10.12954/PI.14043
Source DB: PubMed Journal: Prostate Int ISSN: 2287-8882
Distribution of comorbidities in M-TURP and PK-TURP patients
| Comorbidity | Operation modality
| Total | |
|---|---|---|---|
| M-TURP | PK-TURP | ||
| HT | 68 | 72 | 140 |
| HT+CAD | 12 | 15 | 27 |
| COPD | 16 | 14 | 30 |
| DM | 15 | 12 | 27 |
| HT+COPD | 5 | 8 | 13 |
| HT+CAD+DM | 18 | 20 | 38 |
| HT+CAD+COPD | 7 | 6 | 13 |
| HT+DM | 10 | 13 | 23 |
| HT+DM+COPD | 1 | 2 | 3 |
| DM+COPD | 2 | 1 | 3 |
| Total | 154 | 163 | 317 |
| 0.978 | |||
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the prostate; HT, hypertension; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.
Preoperative characteristics of the patients
| Operation modality | Age (yr) | Prostate volume (mL) | IPSS | Qmax (mL/sec) | PVR volume (mL) | IIEF |
|---|---|---|---|---|---|---|
| M-TURP (n=154) | 64.4±8.3 | 42.6±12.6 | 19.3±7.9 | 8.7±2.8 | 122.0±61.0 | 16.8±6.3 |
| PK-TURP (n=163) | 69.0±8.0 | 72.2±25.4 | 25.6±7.6 | 8.5±4.2 | 131.5±73.7 | 15.1±8.5 |
| 0.00 | 0.00 | 0.00 | 0.96 | 0.51 | 0.23 |
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the prostate; IPSS, International Prostate Symptom Score; Qmax, maximum flow rate; PVR, postvoid residual; IIEF, International Index of Erectile Function.
Fig. 1.Percentage of urethral stricture in the treatment arms. M, monopolar; PK, plasmakinetic; TURP, monopolar transurethral resection of the prostate. *P=0.025.
Distribution of comorbidities in M-TURP and PK-TURP patients with urethral stricture complication
| Comorbidity | Urethral stricture
| Total | |
|---|---|---|---|
| Absent | Present | ||
| HT | 137 | 3 | 140 |
| HT+CAD | 24 | 3 | 27 |
| COPD | 29 | 1 | 30 |
| DM | 27 | 0 | 27 |
| HT+CAD+DM | 28 | 10 | 38 |
| HT+CAD+COPD | 12 | 1 | 13 |
| HT+DM | 19 | 4 | 23 |
| HT+DM+COPD | 2 | 1 | 3 |
| DM+COPD | 3 | 0 | 3 |
| HT+COPD | 13 | 0 | 13 |
| Total | 294 | 23 | 317 |
| 0.000 | |||
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the prostate; HT, hypertension; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus.
P<0.05.
Multivariate analysis of risk factors in M-TURP and PK-TURP patients with urethral stricture complication
| Risk factor | OR | 95% CI | |
|---|---|---|---|
| Age | 1.253 | 1.046–1.272 | 0.004 |
| Prostate volume | 1.053 | 1.030–1.076 | 0.000 |
| HT+DM | 9.917 | 1.646–59.743 | 0.012 |
| HT+CAD | 1.638 | 0.274–9.786 | 0.589 |
| HT+ DM+CAD | 14.959 | 3.427–65.303 | 0.000 |
M, monopolar; PK, plasmakinetic; TURP, transurethral resection of the prostate; OR, odds ratio; CI, confidence interval; HT, hypertension; DM, diabetes mellitus; CAD, coronary artery disease.